Neuphoria Therapeutics (STU:B1N0) Net Change in Cash : €-7.65 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Neuphoria Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Neuphoria Therapeutics's Net Change in Cash for the three months ended in Dec. 2024 was €-3.58 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was €-7.65 Mil.

Neuphoria Therapeutics Net Change in Cash Historical Data

The historical data trend for Neuphoria Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuphoria Therapeutics Net Change in Cash Chart

Neuphoria Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Net Change in Cash

Get a 7-Day Free Trial

-5.74

14.92

3.30

-9.88

0.47

Neuphoria Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Net Change in Cash	Get a 7-Day Free Trial															-3.72	1.86	-	-4.08	-3.58

Neuphoria Therapeutics Net Change in Cash Calculation

Neuphoria Therapeutics's Net Change in Cash for the fiscal year that ended in Jun. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-13.639	+	0	+	14.036	+	0.072
	=	0.47

Neuphoria Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -3.207 + 0 + -0.107 + -0.265

= -3.58

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Neuphoria Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuphoria Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuphoria Therapeutics Inc (STU:B1N0) » Definitions » Net Change in Cash

Comparable Companies

UBX CRIS NNVC CDIO BIVI CVM LSTA MURA ABVC ALLK VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

NEUP:USA

Address

100 Summit Dr, Burlington, MA, USA, 01803

Website

https://www.bionomics.com.au

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Neuphoria Therapeutics Headlines

No Headlines